Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Stattic pretreatment for 6 h did not block calcitriol-induced PD-L1 upregulation; instead, increased PD-L1 expression was observed (Figure S4), indicating that vitamin D/VDR regulation of PD-L1 is Stat-3 independent.

Source: 3. Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

To target vitamin D/VDR, we have developed MeTC7, which inhibits PD-L1 expression in vitro and in vivo and provides a new approach to block PD-L1/PD-1-driven tumorigenesis.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1

Study design awaiting verification · Cancers · 2023

Original publication title

Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1

Negar Khazan; Emily R. Quarato; Niloy A. Singh; Cameron W. A. Snyder; Taylor Moore; John P. Miller; Masato Yasui; Yuki Teramoto; Takuro Goto; Sabeeha Reshi; Jennifer Hong; Naixin Zhang; Diya Pandey; Priyanka Srivastava; Alexandra Morell; Hiroki Kawano; Yuko Kawano; Thomas Conley; Deepak M. Sahasrabudhe; Naohiro Yano; Hiroshi Miyamoto; Omar Aljitawi; Jane Liesveld; Michael W. Becker; Laura M. Calvi; Alexander S. Zhovmer; Erdem D. Tabdanov; Nikolay V. Dokholyan; David C. Linehan; Jeanne N. Hansen; Scott A. Gerber; Ashoke Sharon; Manoj K. Khera; Peter W. Jurutka; Natacha Rochel; Kyu Kwang Kim; Rachael B. Rowswell-Turner; Rakesh K. Singh; Richard G. Moore

© 2023 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

Abstract: Simple Summary

Programmed death-ligand 1 (PD-L1) enables immune evasion of tumors. Antibodies targeting PD-L1/PD-1 exhibit durable responses in eligible patients. However, antibodies cause life-threatening toxicities. Small molecules targeting PD-L1, or the drivers of PD-L1 or PD-L1/PD-1 axis, are being explored as alternatives. Thus, identifying vitamin D/vitamin D receptor (VDR) as the driver of PD-L1 expression in AML significantly enhances our understanding of the origin of PD-L1-driven immune evasions in AML and malignancies of pancreas and ovaries, where similar transcriptional regulation has been observed.

To target vitamin D/VDR, we have developed MeTC7, which inhibits PD-L1 expression in vitro and in vivo and provides a new approach to block PD-L1/PD-1-driven tumorigenesis.

Source: Simple Summary

Abstract: Abstract

Small-molecule inhibitors of PD-L1 are postulated to control immune evasion in tumors similar to antibodies that target the PD-L1/PD-1 immune checkpoint axis. However, the identity of targetable PD-L1 inducers is required to develop small-molecule PD-L1 inhibitors. In this study, using chromatin immunoprecipitation (ChIP) assay and siRNA, we demonstrate that vitamin D/VDR regulates PD-L1 expression in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cells. We have examined whether a VDR antagonist, MeTC7, can inhibit PD-L1. To ensure that MeTC7 inhibits VDR/PD-L1 without off-target effects, we examined competitive inhibition of VDR by MeTC7, utilizing ligand-dependent dimerization of VDR-RXR, RXR-RXR, and VDR-coactivators in a mammalian 2-hybrid (M2H) assay.

MeTC7 inhibits VDR selectively, suppresses PD-L1 expression sparing PD-L2, and inhibits the cell viability, clonogenicity, and xenograft growth of AML cells. MeTC7 blocks AML/mesenchymal stem cells (MSCs) adhesion and increases the efferocytotic efficiency of THP-1 AML cells. Additionally, utilizing a syngeneic colorectal cancer model in which VDR/PD-L1 co-upregulation occurs in vivo under radiation therapy (RT), MeTC7 inhibits PD-L1 and enhances intra-tumoral CD8+T cells expressing lymphoid activation antigen-CD69. Taken together, MeTC7 is a promising small-molecule inhibitor of PD-L1 with clinical potential.

Source: Abstract
Authors’ abstract

Simple Summary

Programmed death-ligand 1 (PD-L1) enables immune evasion of tumors. Antibodies targeting PD-L1/PD-1 exhibit durable responses in eligible patients. However, antibodies cause life-threatening toxicities. Small molecules targeting PD-L1, or the drivers of PD-L1 or PD-L1/PD-1 axis, are being explored as alternatives. Thus, identifying vitamin D/vitamin D receptor (VDR) as the driver of PD-L1 expression in AML significantly enhances our understanding of the origin of PD-L1-driven immune evasions in AML and malignancies of pancreas and ovaries, where similar transcriptional regulation has been observed.

To target vitamin D/VDR, we have developed MeTC7, which inhibits PD-L1 expression in vitro and in vivo and provides a new approach to block PD-L1/PD-1-driven tumorigenesis.

Abstract

Small-molecule inhibitors of PD-L1 are postulated to control immune evasion in tumors similar to antibodies that target the PD-L1/PD-1 immune checkpoint axis. However, the identity of targetable PD-L1 inducers is required to develop small-molecule PD-L1 inhibitors. In this study, using chromatin immunoprecipitation (ChIP) assay and siRNA, we demonstrate that vitamin D/VDR regulates PD-L1 expression in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cells. We have examined whether a VDR antagonist, MeTC7, can inhibit PD-L1. To ensure that MeTC7 inhibits VDR/PD-L1 without off-target effects, we examined competitive inhibition of VDR by MeTC7, utilizing ligand-dependent dimerization of VDR-RXR, RXR-RXR, and VDR-coactivators in a mammalian 2-hybrid (M2H) assay.

MeTC7 inhibits VDR selectively, suppresses PD-L1 expression sparing PD-L2, and inhibits the cell viability, clonogenicity, and xenograft growth of AML cells. MeTC7 blocks AML/mesenchymal stem cells (MSCs) adhesion and increases the efferocytotic efficiency of THP-1 AML cells. Additionally, utilizing a syngeneic colorectal cancer model in which VDR/PD-L1 co-upregulation occurs in vivo under radiation therapy (RT), MeTC7 inhibits PD-L1 and enhances intra-tumoral CD8+T cells expressing lymphoid activation antigen-CD69. Taken together, MeTC7 is a promising small-molecule inhibitor of PD-L1 with clinical potential.

Publication and source details

Original title: Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1

Negar Khazan; Emily R. Quarato; Niloy A. Singh; Cameron W. A. Snyder; Taylor Moore; John P. Miller; Masato Yasui; Yuki Teramoto; Takuro Goto; Sabeeha Reshi; Jennifer Hong; Naixin Zhang; Diya Pandey; Priyanka Srivastava; Alexandra Morell; Hiroki Kawano; Yuko Kawano; Thomas Conley; Deepak M. Sahasrabudhe; Naohiro Yano; Hiroshi Miyamoto; Omar Aljitawi; Jane Liesveld; Michael W. Becker; Laura M. Calvi; Alexander S. Zhovmer; Erdem D. Tabdanov; Nikolay V. Dokholyan; David C. Linehan; Jeanne N. Hansen; Scott A. Gerber; Ashoke Sharon; Manoj K. Khera; Peter W. Jurutka; Natacha Rochel; Kyu Kwang Kim; Rachael B. Rowswell-Turner; Rakesh K. Singh; Richard G. Moore

Cancers · 2023

* Correspondence: peter.jurutka@asu.edu (P.W.J.); rakesh_singh@urmc.rochester.edu (R.K.S.); Tel.: +1-602-543-6087 (P.W.J.); +1-585-276-6281 (R.K.S.)© 2023 by the authors.2023https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).University of Rochester CTSAUL1 TR002001National Center for Advancing Translational Sciences of the National Institutes of HealthTechnology Development Fund of the University of RochesterNational Institutes of HealthR35 GM1348641RF1 AG071675-011R01 AT012053Passan FoundationNational Science Foundation2210963This research was funded by the University of Rochester CTSA award number UL1 TR002001, from the National Center for Advancing Translational Sciences of the National Institutes of Health, and the Technology Development Fund of the University of Rochester award to R.K.S., S.G., D.L., and R.M. N.V.D. acknowledges following funding: National Institutes of Health, Grant/Award Numbers: R35 GM134864, 1RF1 AG071675-01, 1R01 AT012053; Passan Foundation; National Science Foundation, Grant/Award Number: 2210963. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T06:54:32.918877+00:00

DOI: 10.3390/cancers15133432 · PMC10340436